Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Keratosis, Actinic 1Glioblastoma 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 196Cisplatin 188Magnetic Resonance Spectroscopy 167Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 117Paclitaxel 112Oxaliplatin 110Biopsy 105venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 69sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Imipramine × Clear all
NCT06778434 2025-12-22

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

VA Office of Research and Development

Phase 2 Recruiting
48 enrolled
Dermatologic

Keratosis, Actinic

NCT04863950 2025-08-27

Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

The University of Texas Health Science Center at San Antonio

Phase 2 Recruiting
25 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡